December 2008 Briefing - Dermatology
Here are what the editors at HealthDay consider to be the most important developments in Dermatology for December 2008. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Masseteric Muscle Hypertrophy Treated with Botulinum Toxin
MONDAY, Dec. 29 (HealthDay News) -- Botulinum toxin (BoNT) type A is a new, safe and effective non-invasive therapy for treatment of masseteric muscle hypertrophy to obtain lower facial contouring, according to research published in the November issue of the Journal of Craniofacial Surgery.
Ultrasound Imaging Used to Guide Laser Fat Removal
FRIDAY, Dec. 19 (HealthDay News) -- Ultrasound imaging may be applied to guide laser fat removal, according to the results of a study reported in the December issue of Lasers in Surgery and Medicine.
Psoriasis Associated with Higher Risk of Hyperleptinemia
WEDNESDAY, Dec. 17 (HealthDay News) -- Psoriasis has been linked to hyperleptinemia, which in turn is associated with a higher risk of developing metabolic syndrome, according to research published in the December issue of the Archives of Dermatology.
IL-21 and Receptor Appear to Play Atopic Dermatitis Role
WEDNESDAY, Dec. 17 (HealthDay News) -- Expression of the cytokine IL-21 and its receptor, IL-21R, is upregulated in skin lesions of atopic dermatitis in humans and also in a mouse model of allergic skin inflammation, according to research published online Dec. 15 in the Journal of Clinical Investigation.
Teens' Indoor Tanning Rate Unaffected By Legislation
THURSDAY, Dec. 11 (HealthDay News) -- Legislation restricting teens' access to indoor tanning does little to reduce its prevalence because most states with restrictions permit use with parental permission, according to a report published online Dec. 10 in Cancer.